Skip to main content
Clinical Trials/ACTRN12616000718448
ACTRN12616000718448
Suspended
未知

A Feasibility Study to Assess Safety and Efficacy of the Transapical and Transfemoral JenaValve Pericardial TAVR (Transcatheter Aortic Valve Replacement) System in the Treatment of Patients with Symptomatic Severe Aortic Regurgitation (AR)

JenaValve Technology, Inc.0 sites15 target enrollmentMay 30, 2016

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
JenaValve Technology, Inc.
Enrollment
15
Status
Suspended
Last Updated
6 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
May 30, 2016
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\. Patient with severe aortic regurgitation (AR) assessed by echocardiography
  • 2\. Patient at high risk for open surgical valve replacement
  • 3\. Patient symptomatic according to NYHA functional class II or higher.

Exclusion Criteria

  • 1\. Congenital uni\- or bicuspid aortic valve morphology
  • 2\. Previous prosthetic aortic valve (bioprosthesis or mechanical) implant
  • 3\. Endocarditis or other active infection
  • 4\. Need for urgent or emergent TAVR procedure for any reason
  • 5\. Cardiogenic shock or hemodynamic instability requiring inotropic support or ventricular assist device

Outcomes

Primary Outcomes

Not specified

Similar Trials